Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

A novel and potent series of ene-amides featuring azetidines has been developed as FabI inhibitors active against drug resistant Gram-positive pathogens particularly staphylococcal organisms. Most of the compounds from the series possessed excellent biochemical inhibition of Staphylococcus aureus Fa...

Full description

Saved in:
Bibliographic Details
Main Authors: Takhi, M., Sreenivas, K., Reddy, C.K., Munikumar, M., Praveena, K., Sudheer, P., Rao, B.N.V.M., Ramakanth, G., Sivaranjani, J., Mulik, S., Reddy, Y.R., Narasimha Rao, K., Pallavi, R., Lakshminarasimhan, A., Panigrahi, S.K., Antony, T., Abdullah, I., Lee, Y.K., Ramachandra, M., Yusof, R., Rahman, N.A., Subramanya, H.
Format: Article
Language:English
Published: 2017
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Tenaga Nasional
Language: English
Description
Summary:A novel and potent series of ene-amides featuring azetidines has been developed as FabI inhibitors active against drug resistant Gram-positive pathogens particularly staphylococcal organisms. Most of the compounds from the series possessed excellent biochemical inhibition of Staphylococcus aureus FabI enzyme and whole cell activity against clinically relevant MRSA, MSSA and MRSE organisms which are responsible for significant morbidity and mortality in community as well as hospital settings. The binding mode of one of the leads, AEA16, in Escherichia coli FabI enzyme was determined unambiguously using X-ray crystallography. The lead compounds displayed good metabolic stability in mice liver microsomes and pharmacokinetic profile in mice. The in vivo efficacy of lead AEA16 has been demonstrated in a lethal murine systemic infection model. © 2014 Published by Elsevier Masson SAS.

Similar Items